Efficacy and Safety of CDP870 400 mg Subcutaneously Versus Placebo in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Have Previously Failed at Least One DMARD.

Trial Profile

Efficacy and Safety of CDP870 400 mg Subcutaneously Versus Placebo in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Have Previously Failed at Least One DMARD.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2010

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms FAST4WARD
  • Most Recent Events

    • 05 Nov 2010 Results assessing the impact of treatment on household productivity will be presented at the American College of Rheumatology's 2010 Annual Scientific Meeting, according to a UCB media release.
    • 28 Jul 2010 Status changed from completed to active, no longer recruiting.
    • 19 Jun 2010 Tolerability results presented at the 11th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top